Mutation count, a potential surrogate for tumor mutation load, of circulating tumor DNA (ctDNA) using targeted panel sequencing correlates with clinical outcomes in late stage lung adenocarcinoma and small cell lung cancer.

12045Background: Studies show that mutation count can be used as a biomarker to predict whether or not a patient may respond to immunotherapy or chemoradiation therapy. However, mutation count is u...